Intellia Therapeutics, Inc. (NTLA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

10/25

Growth 2 Margin 2 Expansion 3 Platform 1 Financial 2

latest quarter score

Earnings Reports

10
Intellia (NTLA) Q2 2026: 87% HAE Attack Reduction Sets Stage for First In Vivo Gene Editing Launch
August 06, 2026
11
Intellia Therapeutics (NTLA) Q4 2025: Lombosi Phase 3 Enrollment Surpasses 80, Paving Path to First CRISPR Launch
February 26, 2026
9
Intellia Therapeutics (NTLA) Q3 2025: Clinical Hold Disrupts NEXE Progress as 650+ Patient Data Underpins Safety Analysis
November 07, 2025
10
Intellia (NTLA) Q2 2025: Magnitude Trial Expands 57% to 1,200 Patients, Sharpening Competitive Edge
August 07, 2025
9
Intellia (NTLA) Q1 2025: Phase 3 Enrollment Surges Past 90 Sites, Accelerating Path to First Launch
July 07, 2025

Browse all companies